Zenas BioPharma, Inc. (NASDAQ:ZBIO) Financings
Financings
| Raise | Date |
|---|---|
| Private placement of common stock Announced: about US$120M · US$19 a share · Jefferies +1 Dealers: Jefferies (co-lead), Evercore ISI (co-lead) Insiders: Certain directors and officers of the Company participate at a price of $20.85 per share | Oct 8, 2025 |
| Royalty funding (5.5% royalty on worldwide net sales of obexelimab) Announced: up to US$300M · Evercore Dealers: Evercore Buyers: Royalty Pharma plc (up to $300 million in funding in exchange for a 5.5% royalty on worldwide net sales of obexelimab) Use of proceeds: Obexelimab development and a potential IgG4-RD commercial launch in the first half of 2027, subject to FDA approval | Sep 2, 2025 |